Title

Lung cancer overview: Focus on newer therapies

Document Type

Article

Publication Date

2015

Abstract

Lung cancer is one of the leading causes of death in the United States. The two major types of lung cancer are small cell lung cancer and non-small cell lung cancer (NSCLC); NSCLC is more common. Screening and prevention rates for lung cancer are poor compared with those for other types of cancer, but have improved in the past couple of years because of recent updates to lung cancer screening guidelines. Treatment varies depending upon the disease stage. The emergence of newer oral agents such as afatinib, crizotinib, nivolumab, and ceritinib has contributed immensely to lung cancer treatment. It is important for pharmacists to stay up-to-date on treatment agents in order to promote patients' well-being.

Publication Title

U.S. Pharmacist

Volume

40

Issue

2

First Page

6

Last Page

8

Comments

This article was published in U.S. Pharmacist, Volume 40, Issue 2, Pages 6-8.

The published version is available at http://www.uspharmacist.com/supplements/s/394/.

Copyright © 2015 Jobson Medical Publishing.

This document is currently not available here.

COinS